Arcturus Therapeutics’ (ARCT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a $63.00 price objective on the biotechnology company’s stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Arcturus Therapeutics currently has an average rating of “Buy” and a consensus price target of $66.75.

Arcturus Therapeutics Trading Down 3.7 %

Shares of NASDAQ ARCT opened at $17.31 on Monday. The stock has a market capitalization of $468.88 million, a PE ratio of -7.80 and a beta of 2.63. The stock’s fifty day simple moving average is $17.61 and its two-hundred day simple moving average is $20.00. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. The firm had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter last year, the firm earned ($0.61) EPS. On average, equities analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. Bank of New York Mellon Corp raised its stake in Arcturus Therapeutics by 3.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 119,181 shares of the biotechnology company’s stock worth $2,902,000 after acquiring an additional 3,578 shares during the last quarter. Quest Partners LLC raised its stake in Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 3,579 shares during the last quarter. XTX Topco Ltd purchased a new position in Arcturus Therapeutics in the 2nd quarter worth $596,000. Point72 DIFC Ltd purchased a new position in shares of Arcturus Therapeutics during the 2nd quarter valued at about $188,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Arcturus Therapeutics during the 2nd quarter valued at about $718,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.